I

Indivior PLC (INDV)

NMS – Real vaqt narxi. Valyuta: USD

38.20

-0.08 (-0.21%)

Bozor ochiq: May 13, 2026, 9:30 AM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

I

Indivior PLC (INDV)

NMS – Real vaqt narxi. Valyuta: USD

38.20

-0.08 (-0.21%)

Bozor ochiq: May 13, 2026, 9:30 AM EDT

07.05.2026

3 Best Momentum Stocks to Buy Now for Big Upside in May 2026

COCO, INDV and MPC stand out as momentum buys as investors apply Richard Driehaus' "buy high and sell higher" strategy.

05.05.2026

Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?

Does Indivior Pharmaceuticals Inc. (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.

05.05.2026

Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know

Indivior Pharmaceuticals Inc. (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

05.05.2026

Wall Street Analysts Predict a 27.76% Upside in Indivior Pharmaceuticals Inc. (INDV): Here's What You Should Know

The mean of analysts' price targets for Indivior Pharmaceuticals Inc. (INDV) points to a 27.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

05.05.2026

Best Momentum Stock to Buy for May 5th

INDV, NVT and AVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2026.

04.05.2026

Indivior Announces $175 Million Accelerated Share Repurchase

RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”).

01.05.2026

Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

Indivior Announces $175 Million Accelerated Share Repurchase

RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”).

30.04.2026

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Q1'26 Total Net Revenue of $317 Million, Up 19% YoY Q1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly Adjusted EBITDA of $164 Million in Q1'26, Up 112% YoY Repurchased Approximately Four Million Shares in Q1'26 for $125 Million Conference Call at 8:00 A.M. EDT Today RICHMOND, Va.

24.04.2026

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery.

16.04.2026

Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings.

Search stocks

Indivior PLC (INDV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Indivior PLC (INDV)

3 Best Momentum Stocks to Buy Now for Big Upside in May 2026

Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?

Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know

Wall Street Analysts Predict a 27.76% Upside in Indivior Pharmaceuticals Inc. (INDV): Here's What You Should Know

Best Momentum Stock to Buy for May 5th

Indivior Announces $175 Million Accelerated Share Repurchase

Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Indivior Announces $175 Million Accelerated Share Repurchase

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse